Medical imaging

JelloX Unveils New Research at ESMO Congress 2023

Retrieved on: 
Tuesday, November 14, 2023
Medicine, Research, Spacecraft, Pathology, Conference, Breast cancer, ESMO, Silicon, Patient, Pharmacy, Risk assessment, Oncology, Cancer, IO, 3D, Biomarker, AI, Neoplasm, Immunotherapy, Medical imaging, Medical device

SANTA CLARA, Calif. and HSINCHU, Nov. 14, 2023 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, is announcing new research and conference milestones, coinciding with its 5th anniversary in November 2023. With significant parts of the medical field starting to leverage AI for pharmaceutical R&D and patient risk assessment, JelloX continues to distinguish itself as an early adopter of AI applied to cancer pathology.

Key Points: 
  • To explore JelloX's AI-powered 3D pathology solutions, please contact: [email protected]
    An influential conference in the European oncology space, ESMO Congress 2023 took place from October 20 to 24 and featured significant dialogue around the latest advancements in immunotherapy (IO), antibody-drug conjugates (ADCs), and AI.
  • Invited to present, JelloX's unique application of AI in 3D pathology for cancer drew significant interest from attendees, and its latest research demonstrated new possibilities for biomarker-based patient screening prior to IO treatments.
  • "We estimate that 40% of cancer patients can benefit from AI-analyzed 3D pathology, especially those undergoing immunotherapy," noted Dr. Lin.
  • Our solutions are critical to matching the right patients to the right drugs and to identifying suitable candidates for pharmaceutical research."

New Report Shows Significant Lung Cancer Survival Rate Gains, Lingering Disparities and Urgent Need for Increased Screening

Retrieved on: 
Tuesday, November 14, 2023
Lung, American Lung Association, Health, Medicaid, Disease, Diagnosis, Canadian Lung Association, Patient, Survival rate, Medicaid coverage gap, COVID-19, Lung cancer, Survival, Congress, Face, Uranium mining, Medical imaging

CHICAGO, Nov. 14, 2023 /PRNewswire/ -- Lung cancer survival rates are improving for everyone, including people of color, according to the American Lung Association's 2023 "State of Lung Cancer" report, released today. The five-year lung cancer survival rate for people of color has increased by 17% in the last two years, helping close the health disparity gap.

Key Points: 
  • American Lung Association's 'State of Lung Cancer' report reveals improvement in survival rate for people of color, examines toll of lung cancer state-by-state
    CHICAGO, Nov. 14, 2023 /PRNewswire/ -- Lung cancer survival rates are improving for everyone, including people of color, according to the American Lung Association's 2023 "State of Lung Cancer" report , released today.
  • We are encouraged by the work being done to eliminate lung cancer stigma, increase lung cancer screening and improve lung cancer treatment," said Harold Wimmer, President and CEO of the American Lung Association.
  • Lung cancer screening with annual low-dose CT scans for those at high risk can reduce the lung cancer death rate by up to 20%.
  • The 2023 "State of Lung Cancer" report highlights that states must do more to reduce the burden of lung cancer and encourages everyone to help end lung cancer.

Advancing Quantitative Imaging: CaliberMRI, Inc. announces QIBA Conformance for Canon Medical Systems USA

Retrieved on: 
Tuesday, November 14, 2023
Magnetic resonance imaging, RSNA, Prostate, Breast, Brain, DWI, Canon Medical Systems Corporation, Liver, ADC, Magnetic resonance, Diffusion, Medical Affairs Bureau, Artificial intelligence, Machine learning, QA/QC, Validation, Standard of care, Doctor of Philosophy, MRI, Health, Medical imaging, Medical device

CaliberMRI, an industry leader in standardization of MRI, announces the successful grant of "QIBA DWI Profile Conformance Certification" to Canon Medical Systems USA (Canon Medical), a key step in integrating qMRI into clinical workflow.

Key Points: 
  • CaliberMRI, an industry leader in standardization of MRI, announces the successful grant of "QIBA DWI Profile Conformance Certification" to Canon Medical Systems USA (Canon Medical), a key step in integrating qMRI into clinical workflow.
  • CaliberMRI and Canon Collaborate to Validate AI for more efficient, reproducible quantitative MRI with RSNA/QIBA Process
    The Radiological Society of North Americas (RSNA) Quantitative Imaging Biomarkers Alliance (QIBA) has partnered with CaliberMRI to help standardize quantitative Magnetic Resonance Imaging (qMRI) to improve patient care through the QIBA Conformance Certification program.
  • We anticipate working with other Canon Medical sites and CaliberMRI on QIBA Profile Conformance to help advance qMRI."
  • "Canon Medical's approach to qMRI and QIBA Conformance is key to moving quantitative imaging to the clinic," says CaliberMRI CEO William Hollander.

Sparrow Bioacoustics Clinches Prestigious Best Tech Award at Tech Forward 2023 Awards

Retrieved on: 
Monday, November 13, 2023
Collection, Atlantic Canada, Tech, Health, Smartphone, Patient, Organization, FDA, Medical imaging

HALIFAX, NS, Nov. 13, 2023 /PRNewswire/ -- In a significant recognition of its pioneering work in medical technology, Sparrow Bioacoustics has been honored with winning the Best Tech Award at the annual Tech Forward 2023 Awards .

Key Points: 
  • HALIFAX, NS, Nov. 13, 2023 /PRNewswire/ -- In a significant recognition of its pioneering work in medical technology, Sparrow Bioacoustics has been honored with winning the Best Tech Award at the annual Tech Forward 2023 Awards .
  • The Best of Tech Award from Tech Forward recognizes organizations who have a unique offering, those who have achieved large milestones, such as FDA approval, and/or have secured large-scale financial partnerships.
  • "Leading the charge in a healthcare revolution, Sparrow Bioacoustics is more people to take control of their health like never before," said Yaroslav Shpak M.D., Co-founder of Sparrow Bioacoustics.
  • To Sparrow Bioacoustics, it's not just about creating another healthcare device; it's about reshaping the future and giving people more control over their health.

Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Hepatology, Magnetic resonance imaging, Therapy, AASLD, Patient, Type 2 diabetes, Fibrosis, Liver, Vikings, NASH, F2, Medical imaging, Pharmaceutical industry, Boston

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting® 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held November 10-14, 2023, in Boston.

Key Points: 
  • The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting® 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held November 10-14, 2023, in Boston.
  • As previously reported, the VOYAGE study successfully achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo.
  • Newly reported findings demonstrated robust and comparable liver fat reductions among patients with or without type 2 diabetes, as well as patients with either F2 or F3 fibrosis.
  • The median relative reduction from baseline in liver fat ranged from 38% to 55% for patients receiving VK2809.

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on: 
Monday, November 13, 2023
Medicine, Calcium, FAI, Chest pain, RCA, Plaque, American Heart Association, Risk, LAD, CCTA, CAD, Patient, Stenosis, Heart, MACE, Coronary artery disease, Blood, University, Late, Death, Cardiology, Splenic infarction, Biomarker, AI, Clinical, Medical imaging, Medical device, Pharmaceutical industry

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points: 
  • Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
  • Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
  • Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
  • We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on: 
Monday, November 13, 2023
Medicine, Calcium, FAI, Chest pain, RCA, Plaque, American Heart Association, Risk, LAD, CCTA, CAD, Patient, Stenosis, Heart, MACE, Coronary artery disease, Blood, University, Late, Death, Cardiology, Splenic infarction, Biomarker, AI, Clinical, Medical imaging, Medical device, Pharmaceutical industry

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points: 
  • Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
  • Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
  • Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
  • We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."

DeepSight™ Technology Introduces NeedleVue™ Solution: Revolutionizing the Future of Ultrasound-Guided Interventional Tool Guidance

Retrieved on: 
Monday, November 13, 2023
RSNA, Safety, Patient, Incidence, Medical imaging

This state-of-the-art ultrasound-guided needle technology ushers in a new era of precision and safety in the field of directed interventional tool guidance, a domain grappling with complexities for several decades.

Key Points: 
  • This state-of-the-art ultrasound-guided needle technology ushers in a new era of precision and safety in the field of directed interventional tool guidance, a domain grappling with complexities for several decades.
  • DeepSight's proprietary NeedleVue solution marries innovative sensor technology with most interventional devices, facilitating real-time verification of placement and significantly reducing procedural guesswork.
  • Conventional technologies often present challenges such as laborious calibration processes, decreased sensitivity, and the necessity for precise angles of incidence.
  • DeepSight's NeedleVue delineates a clear paradigm shift in needle guidance technology by delivering real-time, precision needle tracking that is as portable as it is easy to use.

InMed AI Receives FDA 510(k) clearance for NeuroShield™

Retrieved on: 
Monday, November 13, 2023
Brain, Food, Alzheimer's Disease Neuroimaging Initiative, US Foods, Parkinson's disease, Patient, Medicine, FDA, Neurology, Titration, Medicare, Patent, MRI, United States patent law, Physician, Quality of life, Radiology, Medical imaging, Pharmaceutical industry, Atrophy, Dementia, Epilepsy

CHICAGO, Nov. 13, 2023 /PRNewswire/ -- InMed.AI (InMed Prognostics Inc.), a pioneer in AI-driven predictive analytics using multi-modal data including text, signal, and image (US Patent No.11263749) and the creator of an end-to-end fully automated organ agnostic imaging platform, announced that it has received the US Food and Drug Administration (FDA) 510(k) clearance for NeuroShield™, a fully automated brain geometry-based quantifying analytics tool/cloud platform that uses AI/Deep Net/3D Convolutional Networks to support physicians as a clinical decision support tool for neurologists and neuroradiologists. NeuroShield is currently in clinical use in over 220+ sites across the world. In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics.

Key Points: 
  • In-Med is supported by seed funding from Sriram Natarajan, Founder & CEO of Molbio Diagnostics.
  • The segmentation analysis revealed remarkable accuracy, reliability, and effectiveness of NeuroShield.
  • In addition, it is recommended that patients using the new drugs undergo periodic scans to monitor for any side effectsii.
  • In-Med Prognostics has long recognized the critical role of inclusion and ethnicity in healthcare and is leading the charge in developing solutions tailored to diverse patient populations.

Zynex Submits FDA Application for its Next Generation NMES Device

Retrieved on: 
Monday, November 13, 2023
Sale, NMES, M-Wave, Pain management, Rehabilitation, Patient, Food, FDA, Medical device, Medical imaging

The M-Wave is set to replace its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.

Key Points: 
  • The M-Wave is set to replace its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
  • I believe that this next-generation device will be able to build upon the need for customizable NMES treatments in clinical and home settings."
  • The 510(k) application submission represents a significant milestone in Zynex Medical's commitment to delivering cutting-edge medical devices.
  • This application demonstrates the company's dedication to ensuring that patients have access to the latest innovations in medical technology.